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ABSTRACT
Cyclin-dependent kinases (CDKs) coordinate cell cy-
cle checkpoints with DNA repair mechanisms that to-
gether maintain genome stability. However, the myr-
iad mechanisms that can give rise to genome insta-
bility are still to be fully elucidated. Here, we identify
CDK18 (PCTAIRE 3) as a novel regulator of genome
stability, and show that depletion of CDK18 causes
an increase in endogenous DNA damage and chro-
mosomal abnormalities. CDK18-depleted cells accu-
mulate in early S-phase, exhibiting retarded replica-
tion fork kinetics and reduced ATR kinase signaling
in response to replication stress. Mechanistically,
CDK18 interacts with RAD9, RAD17 and TOPBP1,
and CDK18-deficiency results in a decrease in both
RAD17 and RAD9 chromatin retention in response to
replication stress. Importantly, we demonstrate that
these phenotypes are rescued by exogenous CDK18
in a kinase-dependent manner. Collectively, these
data reveal a rate-limiting role for CDK18 in repli-
cation stress signalling and establish it as a novel
regulator of genome integrity.
INTRODUCTION
The ability of replicating cells to enforce cell cycle check-
points is a fundamental biological process (1) that is
commonly dysregulated in human cancers (2). Cyclin-
dependent kinases (CDKs) are an evolutionary conserved
family of Ser/Thr kinases whose activation and inactivation
regulate and drive cell cycle progression and checkpoints.
Over 20 distinct CDK family members have been described
in vertebrates, which have been implicated in both general
(RNA polymerase-mediated) transcription and transitions
between distinct phases of the cell cycle through specific
substrate phosphorylation (3). For example; the control of
S-phase entry from G1 and the initiation of DNA replica-
tion through origin firing in early S-phase are regulated by
CDK2/cyclin E complexes (4). Additionally, CDK1/cyclin
B activity is rate-limiting for mitotic entry and exit, and to
co-ordinate the metaphase to anaphase transition, during
which accurate chromosome alignment and segregation are
regulated through the spindle assembly checkpoint (5–7).
DNA damage detection and repair is vital to normal
cellular survival. The DNA Damage Response (DDR) is
tightly regulated by an array of protein kinases that en-
ables cells to respond to various types of potentially pro-
mutagenic DNA lesions (8,9). Exemplifying their critical
role in preserving genome integrity, several DDR factors
are themselves mutated in cancer pre-disposing human dis-
eases (10). The DDR works in unison with cell cycle check-
points to facilitate DNA repair mechanisms (11). For ex-
ample, the DDR kinase Ataxia Telangiectasia and RAD3-
related (ATR) regulates cellular responses to replication
stress to control the intra-S-phase checkpoint, latent origin
firing and lesion repair (12,13). This is facilitated by ATR-
dependent phosphorylation of the ssDNA-binding complex
RPA, which acts as a platform for recruitment of RAD17,
RAD9-RAD1-HUS1 (9-1-1) and TOPBP1 effector mod-
ules (14–16) that promote activation and amplification of
ATR kinase activity. While it is established that defects in
either cell cycle checkpoints or the DDR can lead to ge-
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nomic instability and human disease (10,17), we are still
some way from uncovering themyriadmechanisms that can
give rise to genome instability. Further understanding of
the molecular factors that govern genome integrity will im-
prove how we manage and target human diseases such as
cancer (18,19), especially given the central role of protein
kinases, and their validation as targets of therapeutic small
molecules (20,21).
To further our understanding of the mechanisms un-
derlying genome stability, we previously reported a hu-
man genome-wide siRNA screen that identified novel
factors whose loss led to increased genome instability
(22,23). An interesting candidate identified in our screen
was the poorly studied CDK family member termed
CDK18/PCTAIRE3/PCTK3. CDK18 belongs to the PC-
TAIRE family of CDKs, which include human CDK16,
CDK17 and CDK18 (24), all of which share a conserved
PCTAIRE amino acid sequence in the helical -C region of
the kinase N-lobe typically employed by CDKs to bind cog-
nate cyclin partners (Supplementary Figure S1A). CDK18
was first described as a neuronal kinase that phosphory-
lates TAU protein when overexpressed in human brain (25).
Hyper-phosphorylated TAU forms part of the neurofibrilar
tangles associated with Alzheimer’s pathology, and TAU is
a known substrate for multiple proline-directed kinases, in-
cluding several CDKs. Interestingly, murine CDK18 over-
expressed in human cells was recently shown to inter-
act with both cyclin E and cyclin A2, which along with
PKA, slightly enhanced CDK18 kinase activity toward
Retinoblastoma protein (Rb), an in vitro substrate that is
often used as a biochemical surrogate for measuring the ac-
tivity of CDK/cyclin complexes (26). Despite these initial
observations, the cellular function of human CDK18 has
remained elusive.
Here, we report that CDK18 is required to prevent the
accumulation of DNA damage and genome instability by
promoting efficient and robust ATR-mediated replication
stress signaling through efficient chromatin retention of
the key replication stress signaling regulators RAD17 and
RAD9.
MATERIALS AND METHODS
Cell culture
HCT116, HeLa, HEK293 and MRC5VA cells were main-
tained as adherent monolayer cultures in DMEM me-
dia containing 10% fetal bovine serum (FBS) and 1%
penicillin/streptomycin at 37◦C in a humidified atmosphere
of 5% CO2. HeLa Flp-in T-REx and HEK293 Flp-In T-
REx cells (Invitrogen) were maintained in DMEM media
containing 10% FBS and 1% penicillin/streptomycin, sup-
plemented with 4 g/ml Blasticidin S (Melford) and 100
g/ml Zeocin (Invitrogen). HeLa cells stably expressing
GFP-tagged Histone H2B were maintained in identical me-
dia supplemented with 2 g/ml Blasticidin S.
Fluorescence-activated cell sorting (FACS) analysis and cell
cycle profiling
Double thymidine block and release experiments were per-
formed as previously described (27) and levels of Cyclin
E, A, B1, phosphorylated Histone H3 and CDK18 deter-
mined at the indicated time points after release from G1
blockade. Actin was used as a loading control. For S-phase
analysis, cell cultures were pulsed with 10 M BrdU for
15 min, washed in phosphate buffered saline (PBS) and
fixed overnight in 70% Ethanol at −20◦C. Fixed samples
were washed 3 times in PBS before treatment with 5 g of
DNAse1 followed by the addition of 300 l of Propidium
Iodide (50 g/ml) to each sample. FACS acquisition was
carried out using a FACS-Calibur (Becton–Dickinson) and
analyzed by FlowJo (Tree Star, Inc). A total of 10 000 live
cells were gated and quantified for each sample, with each
condition replicated 3 times for each individual experiment.
To arrest cells inG0/G1 phase prior to the restriction point,
the normal growth medium was replaced with serum-free
medium, transfected with 0.5 M siRNA per sample and
serum starved for ∼60 h. Synchronized serum-starved cell
populations were released into serum-containing growth
medium, and 12 h post-release, harvested at the indicated
time-points.
CDK18 siRNA depletion
Briefly, 4 l Dharmafect 1 was mixed with 50 M siRNA
and 1.2× 104 cells were seeded into onewell of a 6-well plate
and transfected. This ratio was scaled appropriately de-
pending on cell number and the surface area utilized. Cells
were harvested at either 48 or 72 h post treatment. siRNA
sequences (Dharmacon ON-TARGET-PLUS) were as fol-
lows: CDK18 siRNA 1: AACAUACGUGAAACUGGA,
CDK18 siRNA 2: GCAAGAUCCUGCACCGGGA,
CDK18 siRNA 3: AAAGGGCGCAGCAAACUGA,
CDK18 siRNA 4: GCUCGGUCCUCUUGGCAGA,
CDK18 siRNA 5: UCAGGUUGCAGCUUCUCUGUU,
CDK18 siRNA 6: UCGGAGGACUGAAGAACGAUU
and Control siRNA: UAAUGUAUUGGAACGCAUA.
CDK18 encoding constructs and stable cell line production
Full length CDK18 cDNA (accession no. BC011526.1)
was cloned from a commercial plasmid (Open Biosystems)
into the Gateway entry vector pDONR221 (Life Technolo-
gies) following a PCR reaction with the CDK18 primers;
CDK18 F:GGGGACAAGTTTGTACAAAAAAGC
AGGCTTGAACAAGATGAAGAACTTTAAGCG and
CDK18 R:GGGGACCACTTTGTACAAGAAAGCTG
GGTTCAGAAGATGCTCTGCCGCCTGTTC. Human
RAD9 cDNA was a kind gift from Prof. Scott Davey’s
laboratory. To generate a kinase-inactive mutant (D281A)
CDK18 or a RAD9 S336A mutant, appropriate muta-
genic primer pairs were designed and mutated plasmids
was generated using standard PCR-based site-directed
mutagenesis. For CDK18 stable cell lines, pDONR221
vectors containing the cDNAs were mixed with LR
clonase and FLAG-pDEST/FRT/TO to generate FLAG-
CDK18/FRT/TO vectors and used to generate tetracycline
inducible HeLa and HEK-293 FLAG-CDK18 stable cell
lines (wild-type (WT) or a kinase-inactive D281A coun-
terpart) as previously described (22,23). All plasmids
were fully sequence verified using a range of external and
internal sequencing primers.
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Cell lysis and Western blotting
Cell lysates were prepared in RIPA buffer, (50 mM Tris-
HCL pH 8.0, 150 mM NaCl, 1% (v/v) NP40, 0.1% (w/v)
SDS and 0.5% (w/v) sodium deoxycholate for 30 min on
ice. Lysates were clarified at 16 000 xg for 20 min. Cellu-
lar fractions were prepared sequentially in buffer A (10 mM
HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 340 mM su-
crose, 10% (v/v) glycerol and 0.1% Triton X-100, Buffer B
(10 mMHEPES pH 7.9, 3 mMEDTA and 0.2 mMEGTA)
and buffer A* (10 mM HEPES pH 7.9, 10 mM KCl, 1.5
mM MgCl2, 340 mM sucrose, 0.1 (v/v) Triton X-100 and
benzonase (50 units/ml, Novagen). All buffers were supple-
mentedwith protease inhibitors tablets and Phostop tablets.
Briefly, cytoplasmic fractions from whole cells were pre-
pared in buffer A on ice for 10min, centrifuged at 1000 g for
5 min and transferred to fresh vials. To prepare nucleoplas-
mic fractions, cell pellets were first washed in buffer A and
then re-suspended in buffer B on ice for 30 min, centrifuged
at 1500 g for 5 min and transferred into fresh vials. Chro-
matin bound fractions were prepared by first washing the
nucleoplasmic pellet in buffer B and re-suspending in buffer
A* on ice for 1 h and centrifuged at 1500 g for 5 min. Gel
electrophoresis was performed using the NuPAGE system
(Invitrogen). Briefly, samples were resolved on 4–12% Bis-
Tris gels in 3-(N-morpholino)propanesulfonic acid (MOPS)
buffer, transferred to a polyvinylidene difluoride (PVDF)
membrane. For quantification, non-saturated bands were
quantified by Image J and normalized to an appropriate
loading control as outline in each figure legend.
Immunoblotting and antibodies
Membranes were incubated with antibodies diluted in PBS
supplemented with 5% milk protein and incubated, with
agitation, overnight at 4◦C. Membranes were subjected
to 3 × 5 min washes in PBS and incubated in appro-
priate secondary antibodies for 1 h at room temperature.
The antibodies used for immunoblotting were as follows:
anti-CDK18 (Santa Cruz Biotechnology: sc-176), anti-
pCDK substrate (phosphor-[K/H]pSP) MultiMab rabbit
Ab mix (Cell Signalling), anti-Cyclin A, anti-Cyclin E
and anti-Cyclin B1 (all from Cell Signaling), anti-Histone
H3 pSer10 (27), anti-CHK1 (Sigma Aldrich), anti-CHK1
pS317 (Cell Signaling), anti-Myc 9B11 clone (Cell Sig-
nalling), anti-RAD9 (Abcam andBethyl laboratories), anti-
RPA2 (Calbiochem), anti-RPA2 pT21 (Abcam), anti-RPA2
pS4/8 (Bethyl Laboratories), anti-KAP1 (Bethyl Laborato-
ries), anti-KAP1 pS824 (Bethyl Laboratories), anti-ATRIP
(Bethyl Laboratories), anti-ATR (Santa Cruz Biotechnol-
ogy), anti-Actin (Abcam), anti-ORC2 (Bethyl Laborato-
ries), anti-RAD17 (Bethyl Laboratories), RAD17 (Santa
Cruz Biotechnology), anti-BrdU (AbD Serotec and BD),
anti-RRM2 (Santa Cruz Biotechnology), HRP-secondary
antibodies (DAKO) and Alexa-Fluor antibodies (Invitro-
gen).
Immunoprecipitation
For purification of FLAG-tagged proteins, 1 mg of a
whole-cell protein extract was incubated with 20 l of pre-
equilibrated M2-anti FLAG beads (Sigma) for 16 h at 4◦C.
For immunoprecipitation using endogenous antibodies, 1–
2 g of antibody was incubated with the sample for 1–2
h before addition to 20 l of washed Protein A/G beads
(Santa Cruz) and incubated on a rotating wheel for 16 h
at 4◦C. Beads were then pelleted and washed three times in
20x bed volume of the lysis buffer. The bound protein was
eluted either by heating the beads at 95◦C for 5 min with 2x
LDS buffer (Invitrogen) or by incubation with FLAG pep-
tide (Sigma) according to manufacturer’s instructions. In-
puts represent ∼1/20th of the extract used for the immuno-
precipitation. For endogenous immunoprecipitations, 2 mg
of a whole-cell protein extract was added to 30 l of pre-
washed Protein G fast flow bead slurry (Calbiochem) to-
gether with 5 g of antibody per mg of whole cell extract,
or no antibody for the bead only control, and incubated on
a rotating wheel for 16 h at 4◦C. Beads were pelleted and
washed in several times for 15 min each wash in 1 ml of
TGN buffer (150 mM NaCl, 10% glycerol and 1% Tween-
20 supplemented with Benzonase). Pelleted beads were then
boiled in 2x LDS buffer supplemented with 3 mM DTT.
Immunofluorescence
A total of 1.2 × 103 cells were seeded onto 200 mm glass
cover slips in 6 well plates and incubated for 24 h for the
cells to adhere. Following appropriate siRNA treatments,
cells were fixed in 100% methanol or 4% PFA for 10 min.
Coverslips were washed briefly in PBS and extracted with
3% BSA, 0.2% Triton-X100 dissolved in PBS for 30 min,
followed by a further brief wash in PBS. Antibodies were
diluted in PBS containing 1% BSA at optimized concentra-
tions and a 100 l aliquot added to each cover slip for 1 h.
This was followed by 3 × 5 min washes in PBS. Secondary
Alexa-Fluor antibodies (1:500) and DAPI (1 g/ml) were
diluted in PBS containing 1% BSA and a 100 l aliquot
added to each cover slip for 1 h. This was followed by 3
× 5 min washes. Processed coverslips were mounted onto
glass slides with 10 l Shandon immuno-mount (Thermo).
Immunofluorescence images were captured on a Nikon
Eclipse T200 inverted microscope (Melville), equipped with
a Hamamatsu Orca ER camera, a 200 W metal arc lamp
(Prior Scientific,UK) and an 60x objective lens. Images were
captured and analyzed using Volocity 3.6.1 software (Im-
provision) and exported as tiff files. In general, scoring for
each individual condition (siRNA, cell line, drug treatment
etc.) within an experiment was carried out on at least 10 sep-
arate fields of view containing between 200–300 cells in to-
tal, andmeans from at least 3 independent experiments were
calculated and plotted with their respective standard errors
of the means (SEM). Statistically significant differences be-
tween cell populations was confirmed using a 2-tailed t-test,
assuming equal variances and are presented on figures as *
= P ≤ 0.05, ** = P ≤ 0.01.
COMET assay
Alkaline COMET assays were performed using the Trevi-
gen kit system according to the manufacturers’ protocol.
Briefly, cells were re-suspended at 1× 105 perml in lowmelt-
ing point agarose and transferred to the COMET slide. Af-
ter setting, slides were incubated for 30min in lysis solution,
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and then incubated in unwinding solution for 20min. Slides
were then electrophoresed at 21 volts for 30 min before rins-
ing twice in water and once in 70% ethanol. After drying,
cells were stained with SYBRGreen and visualized by fluo-
rescence microscopy. COMET tail moments were analysed
from at least 100 cells per condition using COMETScore
software and from two independent experiments.
DNA fiber analysis
A total of 25 M CldU was added to the cell culture me-
dia and incubated for 20 min before being washed-out with
fresh media. For fork speed, IdU was added at a concen-
tration of 250 M for 20 min. To measure fork restart, 2
mMHUwas added for 2 h and washed out and media con-
taining 250 M IdU was then added to cells for a further
60 min. Cells were washed and re-suspended in PBS, pipet-
ted onto glass slides and left until tacky. A total of 7 l of
spreading buffer (200 mMTris-HCl pH 7.4, 50 mMEDTA,
0.5 (v/v) % SDS) was added to the cells, incubated for 2 min
and gently tilted before the buffer reached the bottom edge.
Slides were dried, fixed in MeOH:AcOH at a 3:1 ratio and
left overnight at 4◦C. Incubated slides were denatured in 2.5
M HCl for 1 h, rinsed twice with 1X PBS followed with 2
× 5 min washes in blocking solution (1% (w/v) BSA and
0.1% (v/v) Tween 20 in PBS). Slides were incubated with a
BrdU antibody, washed in PBS 3 times and fixed (3% (v/v)
PFA in PBS) for 10 min. Slides were then incubated with
secondary antibodies, washed three times in PBS before be-
ing mounted with Fluorsheild and sealed with coverslips.
DNA fibers were imaged using an Olympus FV1000 con-
focal microscope, image files exported using Olympus Flu-
oview software. DNA fiber lengths were measured in Im-
ageJ using Tiff images for stained DNA fibers. The scale
was changed using distance in pixels (1024 pixels represents
a distance of 211.761m). CldU and IdU tract lengths were
measured and fork speeds in kb/min were then calculated
by multiplying the distance by 2.59 (that gives the number
of kilobases replicated) and dividing by the length of time
incubated in the thymidine analogues (in the fork speed ex-
periments this was exactly 20 min). The percentage of suc-
cessfully restarted forks was calculated using the number of
forks that had successfully restarted (red and green forks)
divided by the total number of forks counted (red only + red
and green forks) × 100. Statistically significant differences
between cell populations were confirmed using a 2-tailed t-
test, assuming equal variances.
Cytotoxicity and clonogenic survival assays
For MTT cytotoxicity assays, cells were plated at a density
of between 1000–2000 cells/well in 96-well plates (depend-
ing on cell line), and the following day transfected with ap-
propriate siRNA and drug added 2 days later at various
concentrations. After 5 days of growth, MTT reagent was
added to the cells at a final concentration of 3 mg/ml and
incubated at 37◦C for 3 h. The media was removed and re-
placed with 200 l DMSO to solubilize the formazan prod-
uct that was quantified by determining optical density at
540 nm using a spectrophotometric microtitre plate reader.
Cytotoxicity was calculated for each treatment by normal-
ization to appropriate vehicle only controls for each set of
transfectants. For clonogenic survival assays, 500–5000 cells
were plated onto 100 mm dishes in triplicate, allowed to
attach for 4 h and then treated with appropriate doses of
hydroxyurea (HU). When colonies could be observed in
the control plates (10–14 days post-HU), cells were fixed
and stained with methylene blue in methanol (4 g/l) and
colonies composed of≥50 cells were scored. Surviving frac-
tions (SF) were calculated based on the plating efficiency
(fraction of colonies formed in untreated plates) for each
cell population per treatment as; SF = (No. cells counted)
/ (No. cells plated × plating efficiency).
Kinase assays
Tetracycline-inducible Flp-In T-REx HeLa cells stably ex-
pressingN-terminal FLAG taggedCDK18 (WTorD281A)
were grown in 5× 75 cm2 flasks, and CDK18 expression in-
ducedwith 1g/ml Tetracycline for 48 h at 37◦C. Cells were
harvested, washed in PBS and re-suspended in lysis buffer
containing 50 mMTris-HCl (pH 7.4), 10 mMKCl, 1.5 mM
MgCl2, 0.1% v/v Triton X-100, 10% w/v glycerol, 340 mM
sucrose and PhosSTOP Phosphatase inhibitor cocktail and
complete protease inhibitor cocktail tablets (Roche) for 10
min on ice. A total of 4 mg of clarified cell extract was pre-
cleared with Pierce Control Agarose Resin (Thermo Scien-
tific), and FLAG-CDK18 was immunoprecipitated using
anti-FLAG M2 Affinity Gel agarose resin (SIGMA). Im-
munoprecipitated protein was twice washed in high (500
mM NaCl) and low (100 mM NaCl) salt lysis buffer, and
assayed in duplicated using 200 M [ 32P] ATP (20 Ci
32P per assay) in the presence of 10 mM MgCl2 and 10
mMMnCl2 for 30 min at 30◦C. Reactions were terminated
by denaturation in SDS sample buffer prior to separation
by SDS-PAGE and transfer to nitrocellulose membranes.
CDK18 32P-incorporation (autophosphorylation) was de-
tected by autoradiography (bottom panels) and the total
amount of CDK18 in immunoprecipitates was compared
by immunoblotting with anti-CDK18 antibodies (top pan-
els).
RESULTS
CDK18 depletion leads to exhibit elevated amounts of DNA
damage and chromosomal abnormalities
Our human genome-wide siRNA-based screen employed
elevated levels of H2AX inHCT116 colorectal tumor cells
as a marker of increased DNA damage/genome instabil-
ity (22,23). Using this approach, human CDK18 was origi-
nally identified as a strong positive ‘hit’ (z-score = 2.5) and
we subsequently validated this finding in HeLa cells using
a deconvolved siRNA approach from the CDK18 siRNA
pool used within the initial screen (Figure 1A). Based on
these data, two individual siRNAs directed to the trans-
lated region of CDK18 mRNA were selected to carry out
further studies (Figure 1B). In addition to a marked in-
crease in H2AX foci, depletion of CDK18 also resulted
in increased 53BP1 foci and COMET tail moments (Figure
1C and D, respectively), confirming that CDK18-depleted
cells accumulate large numbers of DNA breaks. We also
observed that CDK18-depleted cells contained an elevated
 at R
oyal H
allam
shire H
ospital on July 6, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 2016 5
A
CDK18
Actin
siRNA: Co
ntr
ol
CD
K1
8 s
i1
CD
K1
8 s
i2
C
C
el
ls
 w
ith
 >
4 
53
B
P1
 fo
ci
 (%
)
0
5
40
35
30
25
20
15
10
siRNA
Control CDK18 si1 CDK18 si2
D
siRNA
Control CDK18 si1 CDK18 si2
C
om
et
 ta
il 
m
om
en
t
0
2
4
12
10
8
6
Control siRNA CDK18 si1 CDK18 si2
D
AP
I
53
BP
1
Control siRNA CDK18 si1 CDK18 si2
0
5
C
el
ls
 w
ith
 >
5 
γH
2A
X 
fo
ci
 (%
)
20
10
15
30
25
35
40
siRNA
Control CDK18 si1 CDK18 si2 CDK18 si3 CDK18 si4
B
Control siRNA CDK18 si1 CDK18 si2
D
AP
I
γH
2A
X
**
**
*
*
*
*
*
E
Total multipolar misaligned pseudo-
bipolar
bridges/
lagging
Pe
rc
en
ta
ge
 o
f m
ito
se
s
0
2
14
12
10
8
6
4
16 Control siRNA
CDK18 si1
CDK18 si2
** **
***
* *
Pe
rc
en
ta
ge
 o
f c
el
l p
op
ul
at
io
n
G1
S
G2/M
50
75
100
25
0
0 12 14 18 0 12 14 18 0 12 14 18Hr post-release:
Control CDK18 si1 CDK18 si2
F
C
el
ls
 w
ith
 >
5 
γH
2A
X 
fo
ci
 (%
) Control siRNA
CDK18 si1
CDK18 si2
0
10
20
30
40
50
0 12 18
Time post release (hr)
14
**
****
**
Figure 1. CDK18 depleted cells exhibit increased DNA damage and genome instability. (A) Increased H2AX (>5 nuclear foci/cell) in HeLa cells using
four individual CDK18 siRNAs deconvolved from the siRNA pool originally employed to deplete CDK18 in a genome-wide screen in HCT116 cells.
Data shown represent the average from two independent experiments with associated SEMs (*P ≤ 0.05 compared to control siRNA cells). (B) Left
panel; siRNA mediated depletion of CDK18 in HeLa cells assessed by Western blot. Right panel; increased H2AX in CDK18 deficient cells assessed by
immunofluorescence. (C) Left panel; representative immunofluorescence staining of 53BP1 foci in HeLa cells transfected with the indicated siRNA with
quantification from three independent experiments shown in the right panel with associated SEMs (*P ≤ 0.05, **P ≤ 0.01 compared to control siRNA
cells). (D) Left panel; representative fluorescence map of electrophoresed HeLa nuclei pre-treated with alkaline solution and analyzed using COMET
assay Tritek software, following transfection with indicated siRNA. Right panel; quantification of COMET tail moment in isolated HeLa nuclei following
electrophoresis and transfection with the indicated siRNA. Data shown are from two independent experiments with associated SEMs (*P≤ 0.05 compared
to control siRNA cells). (E) Quantification of chromosomal abnormalities observed in H2B-GFP HeLa cells transfected with either control or the 2
individual CDK18 siRNAs. Mis-aligned chromosomes were visualized with either CENPE or Aurora B immunofluorescence and multi-polar cells were
identified using co-staining with either alpha or gamma tubulin (see Supplementary Figure S1B for representative images). Data shown represent that mean
obtained from at least 3 independent experiments with associated SEMs (*P ≤ 0.05, **P ≤ 0.01 compared to control siRNA cells). (F) Left panel; cell
cycle distributions of RPE-1 cells transfected with either control or two independent CDK18 siRNA at the indicated times following release from serum
starvation. Right panel; average number of H2AX positive cells within the siRNA-transfected populations at the indicated time points. Data shown are
from two independent experiments with associated SEMs (*P ≤ 0.05, **P ≤ 0.01 compared to control siRNA cells).
mitotic chromosomal abnormality index, including mis-
aligned metaphase chromosomes, lagging chromosomes
and anaphase chromosomal bridges (Figure 1E and Supple-
mentary Figure S1B). As such chromosomal abnormalities
can arise from unresolved replication-associated DNA le-
sions and/or defective repair of lesions duringG2-Mcell cy-
cle transition, we carried cell cycle synchronisation/release
time course experiments to further determine the source
of DNA damage in CDK18-depleted cells. As observed in
asynchronous cell populations, G0/G1 enriched CDK18-
depleted cells exhibited increased amounts of DNA dam-
age compared with control siRNA treated cells (Figure 1F).
Unlike control siRNA treated cells that rapidly re-entered
the cell cycle following release, CDK18-depleted cells ex-
hibited a severe delay in re-entering the cell cycle (Fig-
ure 1F) that may be due to the higher amounts of DNA
damage prevalent within these cells. Unexpectedly, con-
trol siRNA-transfected cells exhibited an increase in DNA
damage upon release back into the cell cycle that started
to reduce over time (Figure 1F). Interestingly, CDK18-
depleted cells exhibited greater amounts ofDNAdamage as
they started to transit into S-phase (Figure 1F), suggesting
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that such damage may be a consequence of aberrant DNA
replication-associated processes. Collectively, these pheno-
typic findings corroborate our screening data, identifying
human CDK18 as a novel regulator of genome stability.
CDK18 is required for efficient S-phase transit
Given that several CDKs are known to control cell cycle
progression, we next assessed the cell cycle distribution of a
CDK18-depleted cell population. CDK18 expression levels
remained constant as cells progressed synchronously from
G1 through the cell cycle, as revealed by double thymidine
block and release experiments (Figure 2A). Although we
observed no gross overall differences in cell cycle distribu-
tion in CDK18-depleted cells using FACS-based propid-
ium iodide (PI) quantification (data not shown), more sen-
sitive FACS-based BrdU incorporation assays in conjunc-
tion with PI staining revealed an increase in the number of
early S-phase cells following CDK18 depletion (Figure 2B)
that was confirmed by quantification of EdU incorpora-
tion using an immunofluorescence-based assay (Figure 2C).
These data suggest that CDK18-depleted cells might be ex-
periencing endogenous replication stress, resulting in a re-
tarded transit through S-phase (13), leading us to hypothe-
size that CDK18-deficient cells might have perturbed repli-
cation fork kinetics. We therefore carried out DNA repli-
cation fiber analyses, which confirmed that replication fork
rates in CDK18 depleted cells were around half of those in
cells transfected with non-targeting control siRNA (Figure
2D). Taken together, these data demonstrate that CDK18-
deificent cells experience replication stress and increased en-
dogenous DNAdamage, raising the likelihood that CDK18
may have a key role in regulating aspects of replication stress
signaling.
CDK18-depleted cells exhibit replication stress signalling de-
fects
Replication protein A (RPA) is a single stranded DNA (ss-
DNA) binding trimeric protein complex required for both
normal S-phase progression and replication stress signaling
(15,28). Interestingly, the RPA32 (RPA2) subunit is phos-
phorylated on several serine and threonine residues by mul-
tiple kinases in response to replication stress, which initi-
ates a series of events that helps establish a robust intra-
S-phase checkpoint (29). To investigate a possible link be-
tween CDK18 and RPA, we employed the ribonucleotide
reductase inhibitor HU to induce replication stress and an-
alyzed RPA32 phosphorylation in CDK18 depleted cells by
immunofluorescence using phospho Ser4/8 and phospho
Thr21 antibodies. Compared with control siRNA treated
cells, CDK18-depleted cells exhibited a marked decrease
in phosphorylated RPA32 at these three sites in response
to replication stress (Figure 3A). Given the significance of
pRPA–ssDNA complexes for triggering the activation and
subsequent downstream signaling of the replication stress
kinase ATR, we evaluated whether ATR activity might be
compromised in CDK18-depleted cells. We first assessed
phosphorylation of several established ATR substrates fol-
lowing treatment with HU in both control and CDK18-
depleted cells. For knockdown of CDK18, we employed
four CDK18-specific siRNAs targeting either the open-
reading frame (CDK18 si1 and si2), or the 3′ or 5′ un-
translated regions (UTRs; CDK18 si5 and si6) of CDK18.
Western blot analyses confirmed a consistent reduction in
phosphorylated RPA32 in CDK18-depleted cells, along-
side reduced phosphorylation of the knownATR substrates
CHK1 at Serine 317 and KAP1 at Serine 824 in response
to replication stress (Figure 3B and Supplementary Figure
S1C).
In addition to ATR-mediated substrate phosphorylation
following HU-induced S-phase stress, we also assessed the
direct functional consequences of defective ATR signal-
ing in CDK18-depleted cells. The CDC25A phosphatase
regulates the intra-S-phase checkpoint following replicative
stress, which is facilitated through CHK1-mediated phos-
phorylation of CDC25A and its subsequent ubiquitination
and degradation (30). Consistent with reduced CHK1 ac-
tivation following replication stress, CDK18-depleted cells
also lacked the ability to degrade endogenous CDC25A
in a timely manner in response to replication stress (Fig-
ure 3C). ATR activity is also known to be required for the
restart of stalled replication forks once replication stress
has been alleviated (31,32). Using DNA fiber analyses,
we assessed replication fork restart proficiency in CDK18-
depleted cells, demonstrating that replication fork restart
was inefficient upon removal of the stress (Figure 3D).
Consistent with this more general ATR signaling defect,
CDK18-depleted cells also failed to stabilize the ribonu-
cleotide reductase subunit RRM2 (Figure 3E) that has been
reported to be dependent on ATR activity in response to
replication stress (33). Taken together, these data suggest
that CDK18-depleted cells may be sensitive to replication
stress-inducing agents due to excessive fork stalling and/or
collapse of stalled forks into DNA breaks. Consistently,
HU-treated CDK18-depleted cells contained markedly in-
creased H2AX pan-nuclear staining (Figure 3F and Sup-
plementary Figure S1D) and increased COMET tail mo-
ments (Figure 3G). Finally, CDK18-depleted cells were un-
able to carry out efficient homologous recombination me-
diated repair of DNA breaks (Supplementary Figure S1E)
and exhibited increased sensitivity to HU (Supplementary
Figure S1F). These cellular phenotypes demonstrate that
CDK18 is required for efficient and robust replication stress
signaling.
An intact CDK18 kinase domain is essential for efficient
replication stress signaling
To further elucidate the functional role of CDK18 in ATR-
mediated replication stress signaling, we set out to as-
sess whether wild-type CDK18, or a catalytically inactive
mutant, could rescue specific phenotypes associated with
siRNA depletion. Previous work has established that mu-
tation of the metal-positioning Asp in the ‘DFG’ motif is
a suitable approach to catalytically inactivate kinases, in-
cluding several CDKs (27,34–36), and that it is consistently
more efficient at blocking catalysis than a Lys to Arg substi-
tution in the 3 N-lobe motif (37,38). We therefore mutated
Asp281 of CDK18 toAla to create a kinase-inactivemutant
(Supplementary Figures S1A and S2A). From these con-
structs, we generated tetracycline (tet)-inducible stable cell
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Figure 2. CDK18-depleted cells exhibit S-phase transit defects and heightened replication stress. (A) Western blots of the indicated proteins in extracts
derived from HeLa cells obtained at the indicated times following release from a double-thymidine block (27). (B) FACS-based quantification of S-phase
fraction in HeLa cell populations transfected with either control or individual CDK18 siRNAs for 72 h and then pulsed with BrdU and stained with
propidium iodide. Graph on the left shows the overall S-phase fraction and the graph on the right shows a more detailed breakdown of S-phase stage
based on quantification of the intensity of BrdU and propidium iodide staining. Data shown represent the mean from at least three independent exper-
iments with their respective SEMs (*P ≤ 0.05, **P ≤ 0.01 compared to control siRNA cells). (C) Quantification of S-phase cells using Click-It based
immunofluorescence staining of EdU in HeLa cell populations transfected with either control or 2 individual CDK18 siRNA. Data shown are from three
independent experiments with associated SEMs (**P ≤ 0.01 compared to control siRNA cells). (D) Left panel; average replication fork speeds in MRC5
cells transfected with control or 2 individual CDK18 siRNA, assessed using either CldU or IdU nucleoside analogues and quantified by determining
individual replication tracks using immunofluorescence detection on single DNA fibers. Data shown represent the mean from at least three independent
experiments with associated SEMs (**P ≤ 0.01 compared to control siRNA cells). Right panel; distributions of replication fork speed for the data shown
in the left panel.
lines expressing comparable amounts of either WT FLAG-
CDK18 or kinase-inactive FLAG-D281A CDK18, along-
side a FLAG empty-vector negative control (Parental) and
employed our validated UTR-directed CDK18 siRNA to
deplete endogenous CDK18 mRNA and protein. Consis-
tent with our previous findings, un-induced stable cell lines
transfected with CDK18 UTR-directed siRNA exhibited
ATR signalling defects in response to replication stress (Fig-
ure 4A). Importantly, this defect was partially rescued by
induced expression of WT siRNA-resistant CDK18 cDNA
but not by a D281A kinase-inactive mutant (Figure 4A
and Supplementary Figure S2B), even though both proteins
were expressed at similar (exogenous) levels. Likewise, in-
duced expression of WT CDK18 cDNAwas capable of res-
cuing DNA breaks apparent in cells following CDK18 de-
pletion by UTR-directed siRNA, in marked contrast to the
D281A kinase-inactive mutant (Figure 4B and Supplemen-
tary Figure S2C). Interestingly, the forced expression of the
D281A kinase-inactive CDK18 cDNA also led to a rapid
increase in DNA damage in the absence of exogenous dam-
age, suggesting a possible dominant-negative phenotype in
these cells caused by the presence of the kinase-inactive mu-
tant (Figure 4C and Supplementary Figure S2C). Collec-
tively, these data demonstrate that CDK18 activity is re-
quired to regulate factors essential for maintaining robust
ATR replication stress-signaling and genome stability.
CDK18 interacts with RAD9, RAD17 and TopBP1 and pro-
motes phosphorylation of RAD9
To ascertain whether CDK18 interacts with replication
stress components, we immunoprecipitated endogenous
RAD9, RAD17 and CDK18 proteins from cells treated
with 3 mM HU for 5 h (Figure 5A–C). As previously re-
ported, RAD9 andRAD17 co-purified with each other and
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Figure 3. CDK18-depleted cells fail to elicit robust replication stress signaling. (A) Quantification of phosphorylated RPA2 (phospho Thr21) foci in HeLa
cells transfected with either control or individual CDK18 siRNAs and treated with 3mMHU for 6 h. No significant differences were observed in unstressed
cell populations (Figure 2B, S1C and data not shown). Left panel; representative immunofluorescence staining of RPA2 pT21 and DNA overlay. Right
panel; quantification of RPA2 pT21 and pS4/pS8 foci in siRNA-transfected cell populations from three independent experiments with associated SEMs
(*P ≤ 0.05, **P ≤ 0.01 compared to control siRNA cells). (B) Western blots evaluating phosphorylation of KAP1 at Ser 824, CHK1 at Ser 317 and RPA2
at Thr 21 in HeLa cells transfected as described in (A). Comparable data were obtained with two additional CDK18 siRNAs, as well as in both RPE1 and
U2OS cells (Supplementary Figure S1C). (C) Upper panel; Western blots assessing CDC25A levels in HeLa cells transfected with either control or CDK18
siRNA and treated with 25 g/ml cycloheximide for 5 min followed by 3 mM HU treatment for the indicated time. Comparable data are shown for an
additional CDK18 siRNA in the lower panel. (D) Left panel; schematic representation of the replication restart assay with images of individual DNA fibers
fromMRC5 cells that exhibit efficient (control siRNA) or deficient (CDK18 siRNA) replication restart following the removal of an exogenous replication
stress. Right panel; quantified replication fork restart in MRC5 cells transfected with either control or individual CDK18 siRNA. Data shown are from at
least three independent experiments with associated SEMs (**P≤ 0.01 compared to control siRNA cells). (E) Western blots showing RRM2 expression in
HeLa cells transfected as described in (A). (F) Quantification of H2AX pan-nuclear staining in HeLa cells transfected as described in (A). Representative
images for this data are shown in Supplementary Figure S1D. Data shown are from at least two independent experiments with associated SEMs (*P ≤
0.05, **P ≤ 0.01 compared to control siRNA cells). (G) Quantification of COMET tail moment in isolated HeLa nuclei transfection as described in (A).
Data shown are from two independent experiments with associated SEMs (*P ≤ 0.05, **P ≤ 0.01 compared to control siRNA cells).
with TopBP1. Importantly, endogenous RAD9, RAD17
and TopBP1 all co-purified with endogenous CDK18 (Fig-
ure 5A and B), suggesting that CDK18 is a component
of this complex. Indeed, interaction between RAD9 and
CDK18 was not dependent on the presence of RAD17 and
vice versa (Figure 5C), implying that RAD9 may act as a
common binding partner for both RAD17 and CDK18.
Furthermore, ectopically expressed RAD9 co-purified both
WT and D281A FLAG-CDK18 from induced stable cell
extracts (Figure 5D). Interestingly, we also found that de-
pletion of CDK18 reduced the phosphorylation of RAD9
on proline-directed putative CDK site(s) (Figure 5E and F)
that have previously been shown to be critical for establish-
ing an efficient cellular response to replication stress (39–
41). Based on sequence homology to optimal CDK con-
sensus substrate recognition motifs, we hypothesized that
phosphorylation of a putative CDK site at Ser336 in the C-
terminal tail of RAD9 was the most likely contributor to
the pCDK signal (40). We therefore generated and trans-
fected plasmids expressing either MYC-tagged WT or a
S336A variant of human RAD9 into cells, which were fur-
ther transfected with either control or CDK18 siRNA, and
determined the amount of pCDK in each transfected pop-
ulation through an IP/western blot approach. Compared
 at R
oyal H
allam
shire H
ospital on July 6, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 2016 9
Figure 4. Rescue of CDK18 depletion is dependent on the CDK18 kinase domain. (A) Western blots showing phosphorylation status of KAP1 at Ser 824,
CHK1 at Ser 317 and RPA2 at Thr 21 in parental (left panel), inducible WT (middle panel) and D281 (right panel) FLAG-CDK18 cDNA expressing
HeLa cells lines. Following transfection with either control siRNA or UTR-directed CDK18 siRNA to deplete endogenous (untagged) CDK18, cell
populations were then either mock treated or tetracycline treated (1 g/ml) for 55 h to induced FLAG-CDK18 expression and 3 mM HU was added
for 6 h. Quantification of the phosphorylation status of these ATR substrates is shown in Supplementary Figure S2B. Note that low levels of expression
of FLAG-CDK18 in the -tet samples masks the endogenous CDK18 band, but is not sufficient to rescue UTR-directed CDK18-deficient phenotypes.
(B) Quantification of 53BP1 foci in the indicated cell populations using anti-FLAG antibodies to confirm induced expression of WT FLAG-CDK18 (see
Supplementary Figure S2C for representative images). Data presented are the mean from at least three independent experiments with associated SEMs
**P ≤ 0.01 compared to -tet control siRNA cells). (C) Quantification of 53BP1 foci in the indicated cell populations as described in (B), but for cells
expressing kinase inactive D281 FLAG-CDK18 (see Supplementary Figure S2C for representative images). Data presented are the mean from at least
three independent experiments with associated SEMs (*P ≤ 0.05, **P ≤ 0.01 compared to respective -tet cells).
with control siRNA transfected cells, CDK18 siRNA trans-
fected cells showed an approximate 40% reduction in CDK-
mediated phosphorylation of RAD9, which was compa-
rable to the reduction seen in the S336A mutant RAD9
expressing cells when compared alongside WT RAD9
expressing cells transfected with control siRNA (Figure
5F and Supplementary Figure S2D). Additionally, CDK-
mediated phosphorylation in the S336A mutant was not
as dramatically reduced in CDK18 siRNA transfected cells
compared with those transfected with control siRNA (Fig-
ure 5F and Supplementary Figure S2D), suggesting that
S336 may represent a major CDK18-regulated phosphory-
lation site on humanRAD9. Unfortunately, we were unable
to confirm these findings with endogenous RAD9 due to
low levels of phosphorylation site occupancy at these sites
(data not shown), and could not detect recombinant RAD9
phosphorylation by endogenous CDK18 immunoprecipi-
tated from HU-treated or control extracts using 32P-based
in vitro kinase assays (data not shown). However, based on
these data, we propose that CDK18 promotes phosphory-
lation of RAD9 at sites such as Ser336 that are required for
efficient replication stress responses, although we are cur-
rently unable to determine if this phosphorylation is directly
or indirectly catalyzed by CDK18. Taken together, these
data demonstrate that CDK18 is a key component of the
replication stress-signaling module that promotes robust
ATR-mediated activity in response to replication stress.
CDK18 deficiency leads to reduced chromatin-bound RAD17
and RAD9 in response to replication stress
Based on our depletion, interaction and rescue studies, we
hypothesized that defective ATR recruitment and/or re-
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duced ATR activity at impeded replication forks might ac-
count for the phenotypes encountered in CDK18-depleted
cells. The ATR interacting protein ATRIP mediates ATR
recruitment and activation at stalled replication forks
through binding of phospho RPA-coated ssDNA (42).
ATR kinase activity is further stimulated through recruit-
ment of RAD17, the 9-1-1 complex and TopBP1 signal-
ing modules that are also dependent on RPA coated ss-
DNA for efficient recruitment (14,43,44). We therefore as-
sessed chromatin association of replication stress signal-
ing factors in CDK18-depleted cells. Whilst there were
no observable differences in ATR recruitment in response
to replication stress, CDK18-depleted cells, unlike ATR-
depleted cells, displayed decreased levels of chromatin-
bound RAD17 and RAD9 compared to control cells (Fig-
ure 6A and Supplementary Figure S2E). This finding was
confirmed using RAD17 and RAD9 siRNA (Figure 6B
and Supplementary Figure S2F), although this effect was
not a consequence of an overall reduction in the cellu-
lar levels of RAD17 or RAD9 (Figure 6C). Importantly,
we were able to rescue this defect by ectopic expression
of siRNA-resistant WT, but not D281A kinase-inactive
FLAG-CDK18 (Figure 6D and Supplementary Figure
S2G). To further analyze this defect, we carried out time-
course analyses following induction of replication stress.
As previously observed, CDK18-depleted cells displayed
reduced chromatin-associated RAD17 and RAD9 in un-
stressed conditions compared to control siRNA-transfected
cells (Figure 6E). Following 2 and 4 h of HU exposure,
CDK18-depleted cells exhibited comparable, if not slightly
elevated, levels of chromatin-bound RAD17 and RAD9 to
that observed in control cells. However, after 6 h of HU
treatment, RAD17 and especially RAD9, retention was re-
duced in CDK18-depleted cells compared to controls (Fig-
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ure 6E), which may be a consequence of reduced ATR sig-
naling and heightened replication fork collapse. Consistent
with our previous findings, CDK18-depleted cells also ex-
hibited reduced levels of phosphorylated RPA2 on chro-
matin in response to HU treatment (Figure 6E). Collec-
tively, these data suggest a common regulatory mechanism
through which depletion of CDK18 results in S-phase tran-
sit defects in unstressed cells and defective ATR signaling
upon challenge with replicative stress-inducing agents.
DISCUSSION
The preservation of genomic integrity is vital to safeguard
against potential pro-mutagenic lesions, and together with
a compromised cell cycle, can ultimately lead to abnormal
proliferation and diseases such as cancer. The tightly reg-
ulated ATR-mediated signaling cascade acts as a fail-safe
mechanism through which cells can efficiently respond to
replication stress and ensure accurate duplication of the
genome that can be faithfully passed on to subsequent
cell generations. The enhancement of ATR specific activ-
ity occurs through a complex series of events; while ATR-
mediated phosphorylation of RAD17 aids its retention on
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chromatin, RAD17 recruitment occurs independently of
ATR and like ATRIP/ATR, it too requires RPA–ssDNA
complexes (45). RAD17 recruits the RAD9-RAD1-HUS1
(9-1-1) complex, which completes the signaling module
proposed to preferentially bind RPA coated stalled repli-
cation forks at ssDNA–dsDNA junctions/gapped DNA
structures, and recruitment of the 9-1-1 complex enhances
ATR’s ability to recognize its substrates (45). Given that we
identified reduced chromatin-bound RAD17 and RAD9 in
CDK18-depleted cells, we therefore suggest that in these
cells, ATR activation is below the threshold required to
sustain an amplified replication stress-signalling module
and associated feedback mechanisms. TOPBP1 is also re-
cruited to regions of replication stress through the 9-1-
1 complex, which has been shown to further stimulate
ATR through its activation domain (44). We did not ob-
serve changes in chromatin-associated TOPBP1 in CDK18-
depleted cells, and two recent studies reported a unique
NBS1-dependent pathway by which TOPBP1 is specifi-
cally recruited to stalled replication forks (46,47). In agree-
ment with this alternative mechanism of TOPBP1 recruit-
ment, we observed increased chromatin-associatedNBS1 in
CDK18-depleted cells (Figure 6A). Together with ourDNA
fiber analyses, we therefore propose a model in which cells
with reduced CDK18 expression/activity cannot sustain a
robust ATR-mediated replication stress-signaling module,
leading to heightened collapse of stalled replication forks,
and subsequent generation of DNA breaks and genome in-
stability.
Most CDKs have been shown to require binding of a cog-
nate cyclin partner to elicit a fully active kinase complex
and to confer substrate specificity (48), although several ad-
ditional layers of regulation, which are imparted by phos-
phorylation and specific CDK inhibitors, help ensure cell
cycle fidelity (49). An interaction between CDK18 and Cy-
clin K has previously been described (50), and Cyclin K has
also been reported to interact with CDK9 (51). However,
we were unable to identify any Cyclin-like binding partners
despite detailed proteomic analyses of purified endogenous
and exogenous human CDK18 (data not shown). Recent
work has established that Cyclin K interacts with CDK12
to promote CDK12-mediated phosphorylation of the C-
terminal domain of RNA Polymerase II (52). In doing so,
CDK12/Cyclin K therefore modulates the transcriptional
activity of RNA Polymerase II (POLII) toward a select
panel of DNA damage genes including ATR, CHK1 and
FANCD2 (52). Interestingly, RNA POLII pSer2 and pSer5
levels, which are respective measures of RNA POLII medi-
ated rates of initiation and elongation, were completely un-
affected inCDK18-depleted cells (data not shown), suggest-
ing that CDK18 is not rate-limiting for RNA POLII tran-
scriptional activity. Consistently, no differences in ATR,
CHK1, FANCD2 or Cyclin K protein expression levels fol-
lowing CDK18 depletion were observed (Figure 3B and
Supplementary Figures S1C and S2H), likely ruling out
CDK18 as a rate-limiting member of the transcriptional
sub-family of CDKs.
The PCTAIRE family of CDKs has not been exten-
sively evaluated to date, although the most intensively stud-
ied member PCTAIRE1/CDK16, was recently reported
to be activated by Cyclin Y rather than Cyclin A2, E or
K (53–56). Amino acid comparison of human CDK18,
CDK17 and CDK16 kinase domain sequences with related
CDKs highlights high homology between the three PC-
TAIRE family members in the -C helix motif, where a
Cys residue replaces the Ser residue found in the canonical
CDK PSTAIRE motif (Supplementary Figure S1A). The
high conservation of catalytic residues between all CDK eu-
karyotic protein kinase family members are strongly sug-
gestive of a canonical mode of metal-dependent ATP bind-
ing in the catalytic site of mammalian CDK18 (38,53) that
has only recently been shown to be catalytically active under
very specific in vitro conditions (26). It therefore remains un-
clear how CDK18 activity is regulated in vivo, and although
our work confirms a kinase-dependent role for CDK18 in
promoting efficient replication stress signaling, how this ac-
tivity specifically regulates such signaling is presently un-
clear. It is interesting to note that we find that expression of
a kinase-inactive CDK18 mutant leads to increased DNA
damage, suggestive of a dominant negative phenotype sim-
ilar to that reported for the analogous mutation in CDK1
andCDK2 (57). One possible mechanism bywhich this mu-
tant imparts detrimental effects on the cell cycle is through
the inappropriate sequestration of cyclins (26), which might
reduce the ability of other CDKs to bind cyclins and func-
tion appropriately. Although we did not detect any inter-
action between CDK18 and potential cyclin-binding part-
ners, the mechanisms by which the kinase-inactive mutant
can impact dominant negative effects is worthy of further
investigation. Additionally, further work with specific ki-
nase inhibitors will likely be required to uncover the relative
roles of distinct (proline-directed) cellular kinase activities
of CDK18 in its new role as a regulator of replication stress
signaling.
Finally, in keeping with our findings and the characteris-
tically high levels of genome instability found in many can-
cers (17), interrogation of The human Cancer Genome At-
las database confirms that CDK18 exhibits a copy number
variance gain in ∼15% of annotated breast cancers. Abnor-
mal CDK18 expression and dysregulated ATR signaling
may therefore play a role in the development/progression
of human cancers. As such, we are currently in the process
of evaluating the cellular functions of CDK18 in the con-
text of therapeutic targeting within various cancer subtypes
(20,58).
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Supplementary Figure S1.  
A: Schematic showing alignment of the human PCTAIRE family of CDK16, CDK17 
and CDK18 alongside human CDK1, CDK2, CDK4 and CDK6 paralogues. Purple 
boxes highlight regions of homology, with shading increasing with homology. The red 
box represents the putative cyclin-binding motif and the asterisk identifies the 
conserved aspartic acid (D281) in the DFG magnesium-coordinating site, which was 
mutated to an alanine to create a kinase-inactive (D281A) CDK18 mutant for 
exogenous rescue experiments (see Figure 4). B: Representative images of 
chromosomal alignment defects (white arrows) in metaphase H2B-GFP HeLa cells 
transfected with either control or CDK18 siRNA for the quantified data shown in 
Figure 1E. CENPE (left panel) or Aurora B staining (right panel) was used to 
visualise centromeres, which align along the metaphase plate in control siRNA 
transfections. C: Upper panel; western blots showing phosphorylation status of KAP1 
at Ser 824, CHK1 at Ser 317 and RPA2 at Thr 21 in HeLa cells transfected as 
described in Figure 3B, but using two additional CDK18 siRNA to those described in 
Figure 3B. Lower left and lower right panels show comparable data in RPE1 and 
U2OS cells respectively. D: Representative images of γH2AX pan-nuclear staining in 
control or CDK18 siRNA transfected HeLa cells treated with 3 mM HU for 6hrs for the 
data quantified in Figure 3F. E: Quantification of homologous recombination in 
control and CDK18 siRNA transfected HEK293 cells as assessed by reconstitution of 
an ISce-1-induced double-strand break in an EGFP-based transfected reporter 
plasmid. Data shown is the mean percentage recombination compared with control 
siRNA-transfected cells from at least two independent experiments with associated 
SEMs **p≤0.01 compared to control siRNA cells). F: HU clonogenic survival curves 
for HeLa cells treated with either control or CDK18 siRNA. Data shown represents 
the mean from at least two independent experiments with associated SEMs.  
 
Supplementary Figure S2.  
A: Kinase assays using purified WT or D281A kinase-inactive FLAG-CDK18 as 
indicated from tetracycline-inducible stable HeLa cell lines. Phosphorylated CDK18 
(32P-incorporation by autophosphorylation) was detected by autoradiography (top 
panels) and the total amount of CDK18 within each immunoprecipitate was 
compared by immunoblotting with anti-CDK18 antibodies (bottom panels) to 
	   2	  
demonstrate equal loading. Duplicate lanes for each condition represent 
experimental replicates. B: Quantification of the phosphorylation of the indicated ATR 
substrates in both WT and KD expressing FLAG-CDK18 cells shown in Figure 4A. 
Each phospho signal was normalised to its respective total protein band and is 
represented as a fold change between -tet and +tet cells. C: Left panel; 
representative images of immunofluorescence detection of 53BP1 foci in stable HeLa 
cell lines as described in Figure 4B using anti-FLAG antibodies to confirm induced 
expression of WT FLAG-CDK18. Right panel; representative images of 
immunofluorescence detection of 53BP1 foci in cells as described in Figure 4C using 
anti-FLAG antibodies to confirm induced expression of D281 FLAG-CDK18. D: 
Quantification of pCDK signal in WT and S336A MYC-RAD9 IPs from HeLa cell 
transfected with either control or CDK18 siRNA shown in Figure 6G. Each pCDK 
signal was normalised to that present in control siRNA transfected cells expressing 
WT MYC-RAD9. E: Quantification of the chromatin fraction of the indicated protein in 
CDK18-depleted cells compared with control siRNA treated cells from the data 
presented in Figure 6A. All bands were normalised to ORC2. F: Quantification of the 
chromatin fraction of the indicated protein in untreated (top graph) and HU-treated 
(bottom graph) CDK18-depleted cells compared with control siRNA treated cells from 
the data presented in Figure 6B. All bands were normalised to ORC2. G: 
Quantification of the chromatin fraction of the indicated protein in parental, WT and 
KD expressing FLAG-CDK18 cells shown in Figure 6D. Each signal was normalised 
to its respective ORC2 loading control and is represented as a fold change compared 
to control siRNA treated parental cells (lane 1). H: Western blots evaluating levels of 
ATR, FANCD2 and Cyclin K in HeLa cells transfected with either non-targeting 
control siRNA, or individual siRNA targeting CDK18. Actin levels are used as a 
loading control and CDK18 blots conform efficient knockdown of endogenous CDK18 
following transfection of targeted siRNA. 
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